5QU0

TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 6-[4-(3-CHLORO-4-FLUOROPHENYL)-1-(2-HYDROXYETHYL)-1H-IMIDAZOL-5-YL]IMIDAZO[1,2-B]PYRIDAZINE-3-CARBONITRILE

Summary for 5QU0

• Entry DOI: 10.2210/pdb5qu0/pdb
• Group deposition: Crystal Structures of TGF-beta receptor type 1 kinase domain (T204D) (G_1002109)
• Descriptor: TGF-beta receptor type-1, 6-[4-(3-chloro-4-fluorophenyl)-1-(2-hydroxyethyl)-1H-imidazol-5-yl]imidazo[1,2-b]pyridazine-3-carbonitrile, GLYCEROL, ... (4 entities in total)
• Functional Keywords: alk5, kinase domain, transferase-transferase inhibitor complex, transferase
• Biological source: Homo sapiens (Human)
• Total number of polymer chains: 1
• Total formula weight: 35640.35

Authors

Sheriff, S. (deposition date: 2019-11-19, release date: 2020-02-05, Last modification date: 2024-05-22)

Primary citation

Velaparthi, U.,Darne, C.P.,Warrier, J.,Liu, P.,Rahaman, H.,Augustine-Rauch, K.,Parrish, K.,Yang, Z.,Swanson, J.,Brown, J.,Dhar, G.,Anandam, A.,Holenarsipur, V.K.,Palanisamy, K.,Wautlet, B.S.,Fereshteh, M.P.,Lippy, J.,Tebben, A.J.,Sheriff, S.,Ruzanov, M.,Yan, C.,Gupta, A.,Gupta, A.K.,Vetrichelvan, M.,Mathur, A.,Gelman, M.,Singh, R.,Kinsella, T.,Murtaza, A.,Fargnoli, J.,Vite, G.,Borzilleri, R.M.
Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGF beta R1 Inhibitor as an Immuno-oncology Agent.
Acs Med.Chem.Lett., 11:172-178, 2020

PubMed Abstract: Novel imidazole-based TGFβR1 inhibitors were identified and optimized for potency, selectivity, and pharmacokinetic and physicochemical characteristics. Herein, we report the discovery, optimization, and evaluation of a potent, selective, and orally bioavailable TGFβR1 inhibitor, (BMS-986260). This compound demonstrated functional activity in multiple TGFβ-dependent cellular assays, excellent kinome selectivity, favorable pharmacokinetic properties, and curative efficacy in combination with anti-PD-1 antibody in murine colorectal cancer (CRC) models. Since daily dosing of TGFβR1 inhibitors is known to cause class-based cardiovascular (CV) toxicities in preclinical species, a dosing holiday schedule in the anti-PD-1 combination efficacy studies was explored. An intermittent dosing regimen of 3 days on and 4 days off allowed mitigation of CV toxicities in one month dog and rat toxicology studies and also provided similar efficacy as once daily dosing.

PubMed: 32071685
DOI: 10.1021/acsmedchemlett.9b00552

Experimental method

X-RAY DIFFRACTION (1.67 Å)